Kazia KZIA 深 沪
等待开盘 08-24 09:30:00 美东时间
13.405
-0.265
-1.94%
华盛通- 最 高13.96
- 今 开13.67
- 成交量 14.90万股
- 最 低 13.06
- 昨 收 13.67
- 总市值 1.53亿
- 52周最高 17.40
- 市盈率 静 --
- 换手率 1.30%
- 52周最低 4.86
- 委 比 -33.33%
- 总股本 1142.69万
- 历史最高 744.50
- 量 比 1.13
- 振 幅 6.58%
- 历史最低 3.005
- 每 手 1
- 风险率 2.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29
Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.
08-14 00:31
Kazia Therapeutics Files Provisional Patent Application Supporting Therapeutic Strategy Designed To Prevent Metastatic Recurrence In Patients With High-Risk Early-Stage Triple-Negative Breast Cancer
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the filing of a provisional patent application supporting a novel therapeutic strategy desi...
07-28 19:35
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target
BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $34 price target.
07-16 01:20
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $34.
07-01 19:36
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32
Lake Street initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $32.
06-11 22:53
Kazia Therapeutics任命资深交易专家James Levine为新任CFO
澳大利亚临床阶段肿瘤公司Kazia Therapeutics Limited宣布，任命James Levine为首席财务官，自2026年6月1日起生效。L...
06-02 22:48
